The European Medicines Agency approved 39 new drugs in the first half of the year, PharmaTimes reports. This marks an 11% decline from the 44 it had approved in the first half of 2013 but 6 more than it had in the first half of 2012. The publication points out that a number of the drugs provide treatment for conditions for which there were none before, like GlaxoSmithKline's ($GSK) cancer drug Mekinist and Roche's ($RHHBY) cancer drug Gazyvaro, among others. Story